← ANALYST RATINGS · TIPRANKS
Sol-Gel Technologies (SLGL): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $152, the highest $195, the lowest $110. The average is +137.4% from the last price of $64.25.
Analyst ratings 4
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $81.00 → $66.00−18.5% | Hold | +2.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $82.00 → $67.00−18.3% | Hold | +4.3% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $83.00 → $67.00−19.3% | Hold | +4.3% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $81.00 → $66.00−18.5% | Hold | +2.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $86.00 → $70.00−18.6% | Hold | +8.9% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $83.00 → $68.00−18.1% | Hold | +5.8% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| Imogen Mansfield★★★★★★★★★★#4639 · hits 57% · avg +23.8% | Cantor Fitzgerald | $200 | Buy | +211.3% | Initiated | 14.10.26on TipRanks 06:30 | +2.8%next day −1.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $71.00 → $81.00+14.1% | Hold | +26.1% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $72.00 → $82.00+13.9% | Hold | +27.6% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $71.00 → $83.00+16.9% | Hold | +29.2% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $70.00 → $81.00+15.7% | Hold | +26.1% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $73.00 → $86.00+17.8% | Hold | +33.9% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $72.00 → $83.00+15.3% | Hold | +29.2% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $110 | Buy | +71.2% | Reiterated | 06.10.26on TipRanks 06:55 | −4.7%next day −4.6% · 5 days −9.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $72.00 → $71.00−1.4% | Hold | +10.5% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $73.00 → $72.00−1.4% | Hold | +12.1% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $72.00 → $71.00−1.4% | Hold | +10.5% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $71.00 → $70.00−1.4% | Hold | +8.9% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $74.00 → $73.00−1.4% | Hold | +13.6% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $73.00 → $72.00−1.4% | Hold | +12.1% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| Patrick Dolezal★★★★★★★★★★#1287 · hits 44% · avg +15.1% | LifeSci Capital | $195 | Buy | +203.5% | Assigned | 22.08.26on TipRanks Aug 20 10:55 | +0.7%next day −1.4% · 5 days −8.7% | ↗ |
| Stacy Ku★★★★★★★★★★#2387 · hits 50% · avg +9.3% | TD Cowen | — | Buy | — | Initiated | 29.05.26on TipRanks 05:50 | −2.1%next day −5.0% · 5 days +8.1% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Sol-Gel Technologies
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 06.10.26: target $152 at a price of $78.95 (+93.2%); now: $168 at $64.25 (+162.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 4 | 3 | 3 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-2.07 (from $-3.01 to $-1.54). Last quarter: $-1.13.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About Sol-Gel Technologies
- CEO: Moshe Arkin
- Employees: 28
- 7 Golda Meir Street, Ness Ziona, TA, 7403650, IL
- www.sol-gel.com
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
Data from the stock’s TipRanks forecast page, read 97 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗